ASX - By Stock
|
NSB |
Re:
Ann: Changes to NSB Board
|
|
Phantom1
|
7 |
2.7K |
1 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
7
|
2.7K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Phantom1
|
13K |
6.2M |
6 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
13K
|
6.2M
|
6
|
|
ASX - By Stock
|
FRE |
Re:
Ann: Update on Nasodine Trial and Forward Plans
|
|
Phantom1
|
29 |
9.0K |
0 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
29
|
9.0K
|
0
|
|
ASX - By Stock
|
FRE |
Re:
Ann: Phase 3 Common Cold Trial Results
|
|
Phantom1
|
90 |
33K |
4 |
14/09/23 |
14/09/23 |
ASX - By Stock
|
90
|
33K
|
4
|
|
ASX - By Stock
|
RAC Biotech |
Re:
Large BUY - ex insider/ ex CSO / new consultant - Dr Tillett
|
|
Phantom1
|
143 |
51K |
36 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
143
|
51K
|
36
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex to close IIH Evolve Phase III Clinical Trial
|
|
Phantom1
|
41 |
9.2K |
0 |
21/08/23 |
21/08/23 |
ASX - By Stock
|
41
|
9.2K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
$2 and $1 targets... Yucky wouldn't touch it with yours
|
|
Phantom1
|
438 |
174K |
3 |
10/08/23 |
10/08/23 |
ASX - By Stock
|
438
|
174K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
$2 and $1 targets... Yucky wouldn't touch it with yours
|
|
Phantom1
|
438 |
174K |
9 |
10/08/23 |
10/08/23 |
ASX - By Stock
|
438
|
174K
|
9
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Zantrene AML trial in Israel advances to Phase 2
|
|
Phantom1
|
233 |
81K |
2 |
17/07/23 |
17/07/23 |
ASX - By Stock
|
233
|
81K
|
2
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Phantom1
|
10K |
3.7M |
13 |
07/07/23 |
07/07/23 |
General
|
10K
|
3.7M
|
13
|
|
ASX - By Stock
|
HMD |
Re:
Ann: Dr Ron Weinberger appointed Executive Chairman
|
|
Phantom1
|
44 |
8.8K |
23 |
05/07/23 |
05/07/23 |
ASX - By Stock
|
44
|
8.8K
|
23
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
Phantom1
|
77 |
20K |
4 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
20K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
Phantom1
|
224 |
52K |
7 |
28/06/23 |
28/06/23 |
ASX - By Stock
|
224
|
52K
|
7
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Phantom1
|
20K |
6.9M |
6 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
20K
|
6.9M
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race releases complete cardio-protection data & video
|
|
Phantom1
|
227 |
82K |
17 |
14/04/23 |
14/04/23 |
ASX - By Stock
|
227
|
82K
|
17
|
|
ASX - By Stock
|
HMD |
Re:
Ann: Gold Coast Hospital to begin trial of the HeraCARE Platform
|
|
Phantom1
|
56 |
12K |
13 |
21/03/23 |
21/03/23 |
ASX - By Stock
|
56
|
12K
|
13
|
|
ASX - By Stock
|
HMD |
Re:
Latest at Joondy
|
|
Phantom1
|
3 |
824 |
11 |
20/03/23 |
20/03/23 |
ASX - By Stock
|
3
|
824
|
11
|
|
ASX - By Stock
|
HMD |
Re:
Ann: Ramsay Affiliated Melbourne Mothers Practice Adopts HeraCARE
|
|
Phantom1
|
52 |
12K |
17 |
06/12/22 |
06/12/22 |
ASX - By Stock
|
52
|
12K
|
17
|
|
ASX - By Stock
|
HMD |
Re:
Ann: Ramsay Affiliated Melbourne Mothers Practice Adopts HeraCARE
|
|
Phantom1
|
52 |
12K |
12 |
02/12/22 |
02/12/22 |
ASX - By Stock
|
52
|
12K
|
12
|
|
ASX - By Stock
|
HMD |
Re:
Ann: Ramsay Affiliated Melbourne Mothers Practice Adopts HeraCARE
|
|
Phantom1
|
52 |
12K |
17 |
23/11/22 |
23/11/22 |
ASX - By Stock
|
52
|
12K
|
17
|
|
ASX - By Stock
|
HMD |
Re:
What are the chances of this company?
|
|
Phantom1
|
107 |
27K |
13 |
03/11/22 |
03/11/22 |
ASX - By Stock
|
107
|
27K
|
13
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results of Scheme Meeting
|
|
Phantom1
|
250 |
79K |
5 |
12/09/22 |
12/09/22 |
ASX - By Stock
|
250
|
79K
|
5
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results of Scheme Meeting
|
|
Phantom1
|
250 |
79K |
2 |
07/09/22 |
07/09/22 |
ASX - By Stock
|
250
|
79K
|
2
|
|
ASX - By Stock
|
RAP |
Re:
RAP media thread.
|
|
Phantom1
|
3.3K |
2.5M |
9 |
25/08/22 |
25/08/22 |
ASX - By Stock
|
3.3K
|
2.5M
|
9
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Phantom1
|
132 |
43K |
0 |
21/08/22 |
21/08/22 |
ASX - By Stock
|
132
|
43K
|
0
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Phantom1
|
132 |
43K |
0 |
21/08/22 |
21/08/22 |
ASX - By Stock
|
132
|
43K
|
0
|
|
ASX - By Stock
|
HMD |
Re:
Ann: Notification regarding unquoted securities - HMD
|
|
Phantom1
|
2 |
811 |
2 |
03/08/22 |
03/08/22 |
ASX - By Stock
|
2
|
811
|
2
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Scheme Booklet registered with ASIC
|
|
Phantom1
|
151 |
44K |
2 |
18/07/22 |
18/07/22 |
ASX - By Stock
|
151
|
44K
|
2
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Scheme Booklet registered with ASIC
|
|
Phantom1
|
151 |
44K |
4 |
18/07/22 |
18/07/22 |
ASX - By Stock
|
151
|
44K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Zantrene Improves Immune Therapy Treatment of Melanoma
|
|
Phantom1
|
91 |
33K |
7 |
25/06/22 |
25/06/22 |
ASX - By Stock
|
91
|
33K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Zantrene Improves Immune Therapy Treatment of Melanoma
|
|
Phantom1
|
91 |
33K |
7 |
25/06/22 |
25/06/22 |
ASX - By Stock
|
91
|
33K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Zantrene Improves Immune Therapy Treatment of Melanoma
|
|
Phantom1
|
91 |
33K |
1 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
91
|
33K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Zantrene Improves Immune Therapy Treatment of Melanoma
|
|
Phantom1
|
91 |
33K |
2 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
91
|
33K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Zantrene Improves Immune Therapy Treatment of Melanoma
|
|
Phantom1
|
91 |
33K |
7 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
91
|
33K
|
7
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
Phantom1
|
425 |
123K |
4 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
425
|
123K
|
4
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
Phantom1
|
377 |
141K |
5 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
377
|
141K
|
5
|
|
ASX - By Stock
|
RAP |
Re:
Valuing ResApp Health
|
|
Phantom1
|
466 |
158K |
1 |
30/05/22 |
30/05/22 |
ASX - By Stock
|
466
|
158K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
Valuing ResApp Health
|
|
Phantom1
|
466 |
158K |
1 |
28/05/22 |
28/05/22 |
ASX - By Stock
|
466
|
158K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
Vote NO Pfizer offer
|
|
Phantom1
|
555 |
186K |
1 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
555
|
186K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Termination of Supply Agreement
|
|
Phantom1
|
448 |
250K |
0 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
448
|
250K
|
0
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Termination of Supply Agreement
|
|
Phantom1
|
448 |
250K |
0 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
448
|
250K
|
0
|
|
ASX - By Stock
|
RAP |
Re:
Vote NO Pfizer offer
|
|
Phantom1
|
555 |
186K |
33 |
30/04/22 |
30/04/22 |
ASX - By Stock
|
555
|
186K
|
33
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Quarterly Activities Report and Appendix 4C
|
|
Phantom1
|
98 |
37K |
8 |
26/04/22 |
26/04/22 |
ASX - By Stock
|
98
|
37K
|
8
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Trading Halt
|
|
Phantom1
|
213 |
76K |
15 |
22/03/22 |
22/03/22 |
ASX - By Stock
|
213
|
76K
|
15
|
|
ASX - By Stock
|
RAP |
Re:
COVID-19 Instant Screening test
|
|
Phantom1
|
1.0K |
291K |
0 |
21/03/22 |
21/03/22 |
ASX - By Stock
|
1.0K
|
291K
|
0
|
|
ASX - By Stock
|
RAP |
Re:
COVID-19 Instant Screening test
|
|
Phantom1
|
1.0K |
291K |
17 |
21/03/22 |
21/03/22 |
ASX - By Stock
|
1.0K
|
291K
|
17
|
|
ASX - By Stock
|
RAP |
Re:
Raising awareness of ResAppDx and SleepCheck
|
|
Phantom1
|
52 |
13K |
33 |
11/02/22 |
11/02/22 |
ASX - By Stock
|
52
|
13K
|
33
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Quarterly Activities Report and Appendix 4C
|
|
Phantom1
|
117 |
36K |
20 |
28/01/22 |
28/01/22 |
ASX - By Stock
|
117
|
36K
|
20
|
|
ASX - By Stock
|
RAP |
Re:
RAP media thread.
|
|
Phantom1
|
3.3K |
2.5M |
4 |
25/01/22 |
25/01/22 |
ASX - By Stock
|
3.3K
|
2.5M
|
4
|
|
ASX - By Stock
|
HMD |
Re:
Ann: JHC agrees to full commercial rollout of HeraCARE
|
|
Phantom1
|
110 |
24K |
21 |
24/01/22 |
24/01/22 |
ASX - By Stock
|
110
|
24K
|
21
|
|